Chiranjeevi Padala

Targeting triple-negative breast cancer: Molecular basis and emerging antibody-drug conjugate strategies.

Triple-negative breast cancer (TNBC) accounts for ~10-15% of all breast cancers and is an aggressive, molecularly heterogeneous subtype associated with poor clinical outcomes and limited targeted treatment options. Consequently, systemic therapy has historically relied on chemotherapy, which is often compromised by rec...